CFM
MLTX icon

Cornerstone Financial Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Cornerstone Financial Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11K Buy
57
+29
+104% +$526 ﹤0.01% 1057
2026
Q1 		$522 Buy
+28
New +$464 ﹤0.01% 1166

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cornerstone Financial Management's MLTX Position: Q2 2026 in Review

Cornerstone Financial Management increased its MoonLake Immunotherapeutics (MLTX) stake by 104% in Q2 2026, buying an estimated $526 and bringing the position to 57 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #1057.

Cornerstone Financial Management first reported a position in MLTX in Q1 2026 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Cornerstone Financial Management held 57 shares of MoonLake Immunotherapeutics worth $1.11K as of Q2 2026.
  • Cornerstone Financial Management bought 29 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $526.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q2 2026, its #1057 holding.
  • Cornerstone Financial Management first reported a position in MoonLake Immunotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Cornerstone Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.